Press Releases

Date Title and Summary View
August 14, 2018 Sesen Bio Reports Second Quarter 2018 Financial Results and Pipeline Updates
FDA Grants Fast Track Designation for Vicinium in NMIBC Company Focused on Defining Registration Pathway for Vicinium and Preparing for BLA Submission in 2019 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 14, 2018-- Sesen Bio, Inc. (NASDAQ: SESN), a late-stage clinical company developing next-generation
View HTML
August 9, 2018 Sesen Bio Announces Vicinium Granted Fast Track Designation by FDA for Treatment of Non-Muscle Invasive Bladder Cancer
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 9, 2018-- Sesen Bio, Inc. (Nasdaq: SESN), a late-stage clinical company developing next-generation antibody-drug conjugate (ADC) therapies for the treatment of cancer, today announced that the U.S. Food and Drug Administration ( FDA ) has granted Fast Track
View HTML
August 7, 2018 Sesen Bio Announces CEO and Board Transitions as Company Prepares for 12-Month VISTA Trial Data and Regulatory Submission in 2019
Dr. Thomas Cannell Appointed President and Chief Executive Officer as Company Advances Toward Potential BLA Submission and Commercialization of Vicinium™ Board Members Abbie Celniker, Ph.D. and Paul Chaney Step Down CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 7, 2018-- Sesen Bio, Inc.
View HTML
August 2, 2018 Sesen Bio to Present at the Canaccord Genuity 38th Annual Growth Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 2, 2018-- Sesen Bio, Inc. (Nasdaq: SESN), a late-stage clinical company developing next-generation antibody-drug conjugate therapies for the treatment of cancer, today announced that company management will present a corporate overview at the Canaccord
View HTML
June 4, 2018 Sesen Bio Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares of Common Stock
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 4, 2018-- Sesen Bio, Inc. (Nasdaq: SESN), a late-stage clinical company developing next-generation antibody-drug conjugate therapies for the treatment of cancer, today announced the closing of its previously-announced public offering of 25,555,556 shares of
View HTML
May 31, 2018 Sesen Bio Announces Pricing of Public Offering of Common Stock
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 30, 2018-- Sesen Bio, Inc. (Nasdaq: SESN), a late-stage clinical company developing next-generation antibody-drug conjugate therapies for the treatment of cancer, today announced the pricing of an underwritten public offering of 22,222,223 shares of its
View HTML
May 30, 2018 Sesen Bio Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 30, 2018-- Sesen Bio, Inc. (Nasdaq: SESN), a late-stage clinical company developing next-generation antibody-drug conjugate therapies for the treatment of cancer, today announced that it intends to offer and sell, subject to market conditions, shares of its
View HTML
May 29, 2018 Sesen Bio to Present at the Jefferies 2018 Global Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 29, 2018-- Sesen Bio, Inc. (Nasdaq: SESN), a late-stage clinical company developing next-generation antibody-drug conjugate therapies for the treatment of cancer, today announced that Stephen Hurly, president and chief executive officer of Sesen Bio , will
View HTML
May 21, 2018 Phase 3 Registration Trial for Non-Muscle Invasive Bladder Cancer Achieves 42% Complete Response Rate at Three Months in Carcinoma in Situ Patients
Sesen Bio (Formerly Eleven Biotherapeutics) Reports Positive, Three-Month Data from VISTA Trial of Vicinium™ in High-Grade NMIBC Data Presented During Plenary Session at American Urological Association Annual Meeting Company to Host Conference Call Today at 4:05 p.m. ET CAMBRIDGE, Mass.
View HTML
May 16, 2018 Eleven Biotherapeutics Announces Corporate Name Change to Sesen Bio
Name Change Reflects Company’s Focus on Late-Stage Oncology Drug Development Appointments of Senior Medical Advisor and Vice President of Regulatory Affairs Strengthen Leadership Team as Company Prepares for Phase 3 Three-month NMIBC Data CAMBRIDGE, Mass.
View HTML